Heatwurx (PCSA) Competitors $0.24 0.00 (-0.33%) As of 01:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PCSA vs. LSB, TLPH, DWTX, AEON, NLSP, CLRB, CHRO, KPRX, TSBX, and BMRAShould you be buying Heatwurx stock or one of its competitors? The main competitors of Heatwurx include LakeShore Biopharma (LSB), Talphera (TLPH), Dogwood Therapeutics (DWTX), AEON Biopharma (AEON), NLS Pharmaceutics (NLSP), Cellectar Biosciences (CLRB), Chromocell Therapeutics (CHRO), Kiora Pharmaceuticals (KPRX), Turnstone Biologics (TSBX), and Biomerica (BMRA). These companies are all part of the "pharmaceutical products" industry. Heatwurx vs. Its Competitors LakeShore Biopharma Talphera Dogwood Therapeutics AEON Biopharma NLS Pharmaceutics Cellectar Biosciences Chromocell Therapeutics Kiora Pharmaceuticals Turnstone Biologics Biomerica Heatwurx (NASDAQ:PCSA) and LakeShore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership. Do analysts rate PCSA or LSB? Heatwurx presently has a consensus target price of $2.00, indicating a potential upside of 726.45%. Given Heatwurx's stronger consensus rating and higher possible upside, equities research analysts plainly believe Heatwurx is more favorable than LakeShore Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00LakeShore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, PCSA or LSB? Heatwurx has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, LakeShore Biopharma has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Does the media refer more to PCSA or LSB? In the previous week, Heatwurx and Heatwurx both had 2 articles in the media. Heatwurx's average media sentiment score of 0.73 beat LakeShore Biopharma's score of 0.00 indicating that Heatwurx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heatwurx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LakeShore Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings and valuation, PCSA or LSB? Heatwurx has higher earnings, but lower revenue than LakeShore Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHeatwurxN/AN/A-$11.85M-$3.08-0.08LakeShore Biopharma$80.82MN/A-$61.09MN/AN/A Is PCSA or LSB more profitable? LakeShore Biopharma's return on equity of 0.00% beat Heatwurx's return on equity.Company Net Margins Return on Equity Return on Assets HeatwurxN/A -319.56% -232.40% LakeShore Biopharma N/A N/A N/A Do institutionals & insiders have more ownership in PCSA or LSB? 91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 52.6% of LakeShore Biopharma shares are owned by institutional investors. 9.6% of Heatwurx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryHeatwurx beats LakeShore Biopharma on 8 of the 11 factors compared between the two stocks. Get Heatwurx News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCSA vs. The Competition Export to ExcelMetricHeatwurxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.88M$2.43B$5.58B$9.01BDividend YieldN/A1.80%5.25%4.03%P/E Ratio-0.089.3627.5120.20Price / SalesN/A607.63415.84172.51Price / CashN/A161.3437.0657.97Price / Book0.534.668.085.61Net Income-$11.85M$31.26M$3.17B$248.50M7 Day Performance25.39%6.62%3.57%4.92%1 Month Performance-29.55%3.85%3.74%7.42%1 Year Performance-85.85%3.16%33.78%21.48% Heatwurx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCSAHeatwurx3.7989 of 5 stars$0.24-0.3%$2.00+726.4%-85.3%$2.88MN/A-0.0820Gap UpLSBLakeShore Biopharma0.3628 of 5 stars$0.99-0.4%N/AN/A$9.26M$80.82M0.00773News CoverageGap DownTLPHTalphera1.5867 of 5 stars$0.46+2.7%$5.00+979.9%-43.3%$9.25M$650K-1.0319DWTXDogwood Therapeutics1.3096 of 5 stars$4.60-4.2%$10.00+117.4%N/A$9.17MN/A-0.255Positive NewsAEONAEON Biopharma3.3739 of 5 stars$0.79-5.5%$360.00+45,371.8%-99.0%$8.95MN/A4.405NLSPNLS PharmaceuticsN/A$2.27-7.0%N/A+1,199.1%$8.78MN/A0.006CLRBCellectar Biosciences3.2881 of 5 stars$4.80flat$375.00+7,712.5%-93.3%$8.69MN/A-0.2210CHROChromocell TherapeuticsN/A$1.34+6.3%N/A-87.9%$8.69MN/A-1.084Gap UpHigh Trading VolumeKPRXKiora Pharmaceuticals1.7738 of 5 stars$2.81-1.4%$10.00+255.9%-32.5%$8.68MN/A-0.9710News CoveragePositive NewsTSBXTurnstone Biologics1.5674 of 5 stars$0.37+0.9%$0.45+23.3%-84.0%$8.37MN/A-0.1382BMRABiomerica0.3961 of 5 stars$3.40+4.0%N/A-1.6%$8.32M$5.41M-1.4760 Related Companies and Tools Related Companies LakeShore Biopharma Alternatives Talphera Alternatives Dogwood Therapeutics Alternatives AEON Biopharma Alternatives NLS Pharmaceutics Alternatives Cellectar Biosciences Alternatives Chromocell Therapeutics Alternatives Kiora Pharmaceuticals Alternatives Turnstone Biologics Alternatives Biomerica Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCSA) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heatwurx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heatwurx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
